HF
NKTR icon

HRT Financial’s Nektar Therapeutics NKTR Stock Holding History

HRT Financial’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.08M Sell
70,667
-102,776
-59% -$5.85M 0.01% 986
2025
Q4 		$7.33M Buy
173,443
+160,285
+1,218% +$8.97M 0.02% 583
2025
Q3 		$748K Buy
+13,158
New +$436K ﹤0.01% 1672
2025
Q2 		– Sell
-4,545
Closed -$46K – 3254
2025
Q1 		$46K Buy
+4,545
New +$59.4K ﹤0.01% 2247
2024
Q1 		– Sell
-4,700
Closed -$39K – 2827
2023
Q4 		$39K Buy
4,700
+2,422
+106% +$18.3K ﹤0.01% 1979
2023
Q3 		$20K Sell
2,278
-13,339
-85% -$128K ﹤0.01% 2074
2023
Q2 		$134K Sell
15,617
-9,657
-38% -$103K ﹤0.01% 1931
2023
Q1 		$266K Sell
25,274
-2,756
-10% -$83.4K ﹤0.01% 1785
2022
Q4 		$950K Buy
28,030
+12,510
+81% +$605K 0.01% 1006
2022
Q3 		$744K Buy
15,520
+7,956
+105% +$473K 0.01% 1124
2022
Q2 		$431K Sell
7,564
-15,097
-67% -$953K ﹤0.01% 1775
2022
Q1 		$1.83M Buy
+22,661
New +$3.35M 0.01% 677
2021
Q4 		– Sell
-2,098
Closed -$565K – 3774
2021
Q3 		$565K Buy
2,098
+52
+3% +$12.5K ﹤0.01% 1867
2021
Q2 		$526K Buy
2,046
+463
+29% +$128K ﹤0.01% 1718
2021
Q1 		$474K Buy
+1,583
New +$493K ﹤0.01% 1839
2020
Q4 		– Sell
-1,095
Closed -$272K – 2254
2020
Q3 		$272K Sell
1,095
-90
-8% -$28.3K 0.01% 1205
2020
Q2 		$411K Buy
+1,185
New +$370K 0.01% 860
2020
Q1 		– Sell
-760
Closed -$246K – 1165
2019
Q4 		$246K Sell
760
-182
-19% -$52.8K 0.01% 846
2019
Q3 		$257K Buy
+942
New +$345K 0.01% 1018
2018
Q3 		– Sell
-575
Closed -$421K – 467
2018
Q2 		$421K Buy
+575
New +$663K 0.15% 125

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

HRT Financial's NKTR Position: Q1 2026 in Review

HRT Financial reduced its Nektar Therapeutics (NKTR) stake by 59% in Q1 2026, selling an estimated $5.85M and leaving 70,667 shares worth $5.08M. The position accounts for 0.01% of the portfolio, ranked #986.

HRT Financial first reported a position in NKTR in Q2 2018 and has held it in 20 quarters since. The position peaked at $7.33M in Q4 2025. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • HRT Financial held 70,667 shares of Nektar Therapeutics worth $5.08M as of Q1 2026.
  • HRT Financial sold 102,776 Nektar Therapeutics shares in Q1 2026, an estimated $5.85M.
  • Nektar Therapeutics made up 0.01% of HRT Financial's portfolio in Q1 2026, its #986 holding.
  • HRT Financial first reported a position in Nektar Therapeutics in Q2 2018 and has held it in 20 quarters since.
  • HRT Financial's Nektar Therapeutics position peaked at $7.33M in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.